Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Targeting "bad" B cells in multiple sclerosis: Could laquinimod be part of the armamentarium?
Design of a strong cation exchange methodology for the evaluation of charge heterogeneity in glatiramer acetate.
Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis.
Activity-dependent calcium signalling in oligodendrocyte generation.
Neutrophils and viral-induced neurologic disease.
Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial.
Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.
Sex differences and subclinical retinal injury in pediatric-onset MS.
Free-living Walking Behavior in Persons with Multiple Sclerosis at Increased and Normal Fall Risk: 838 Board #154 June 1, 2: 00 PM - 3: 30 PM.
Dimethyl fumarate may still have a role in progressive multiple sclerosis.
Does the brain listen to the gut?
The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study.
Significant Functional Improvement in a Person with Multiple Sclerosis Utilizing Dynamic Neuromuscular Stabilization: 1333 June 2, 8: 00 AM - 8: 20 AM.
Mannose-binding Lectin Mediated Complement Pathway in Autoimmune Neurological Disorders.
Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy.
Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis.
Neuromyelitis optica spectrum disorders in children and adolescents.
Sick leave and disability pension before and after diagnosis of multiple sclerosis.
[Fingolimod: effectiveness and safety in routine clinical practice. An observational, retrospective, multi-centre study in Galicia].
Cadm3 (Necl-1) interferes with the activation of the PI3 kinase/Akt signaling cascade and inhibits Schwann cell myelination in vitro.
Cognitive Impairment in Multiple Sclerosis.
The role of anti-aquaporin 4 antibody in the conversion of acute brainstem syndrome to neuromyelitis optica.
[May neuroimaging findings of a child with multiple sclerosis surprise us? Clinical and radiological observation].
Mutations in MYT1, encoding the myelin transcription factor 1, are a rare cause of OAVS.
Web-based interventions in multiple sclerosis: the potential of tele-rehabilitation.
Pages
« first
‹ previous
…
823
824
825
826
827
828
829
830
831
…
next ›
last »